Search Results - "Rubío, Rebeca Alba"
-
1
Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A02:01-specific allorestricted T cell receptor transgenic T cells
Published in Oncoimmunology (04-05-2017)“…Background: Chondromodulin-I (CHM1) sustains malignancy in Ewing sarcoma (ES). Refractory ES carries a dismal prognosis and patients with bone marrow (BM)…”
Get full text
Journal Article -
2
Transgenic antigen-specific, HLA-A02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity
Published in Oncoimmunology (02-06-2016)“…Pediatric cancers, including Ewing sarcoma (ES), are only weakly immunogenic and the tumor-patients' immune system often is devoid of effector T cells for…”
Get full text
Journal Article -
3
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Published in Cell death & disease (11-02-2019)“…Ewing sarcoma (EwS) is an aggressive cancer characterized by chromosomal translocations generating fusions of the EWSR1 gene with ETS transcription factors (in…”
Get full text
Journal Article -
4
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo
Published in Oncoimmunology (01-02-2017)“…Pregnancy-associated plasma protein-A (PAPPA), also known as pappalysin, is a member of the insulin-like growth factor (IGF) family. PAPPA acts as a protease,…”
Get full text
Journal Article -
5
Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis
Published in Cancer research (Chicago, Ill.) (15-04-2021)“…Hepatic fat accumulation is associated with diabetes and hepatocellular carcinoma (HCC). Here, we characterize the metabolic response that high-fat…”
Get full text
Journal Article -
6
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets
Published in Oncotarget (05-01-2018)“…Ewing sarcoma is an undifferentiated small-round-cell sarcoma. Although molecular detection of pathognomonic fusions such as enables definitive diagnosis,…”
Get full text
Journal Article -
7
Systematic identification of cancer-specific MHC-binding peptides with RAVEN
Published in Oncoimmunology (02-09-2018)“…Immunotherapy can revolutionize anti-cancer therapy if specific targets are available. Immunogenic peptides encoded by cancer-specific genes (CSGs) may enable…”
Get full text
Journal Article -
8
Abstract 4515: Metabolic stress sensor MondoA mediates in vivo aggressiveness of common ALL by induction of HIF1α
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Tumor cells evolve adaptive mechanisms to survive hypoxia, nutrient deprivation, oxidative or genotoxic stress to ultimately drive tumor progression (Sorensen…”
Get full text
Journal Article -
9
Abstract 2462: MondoA mediates in vivo aggressiveness of common ALL and may serve as a T-cell immunotherapy target
Published in Cancer research (Chicago, Ill.) (15-07-2016)“…Oncogene addiction provides ideal targets for immunotherapy. We previously described MondoA (also known as MLXIP, MAX like protein X interacting protein) as a…”
Get full text
Journal Article -
10
MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress
Published in Blood (24-02-2022)“…Cancer cells are in most instances characterized by rapid proliferation and uncontrolled cell division. Hence, they must adapt to proliferation-induced…”
Get full text
Journal Article -
11
Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding
Published in American journal of human genetics (02-03-2023)“…Ewing sarcoma (EwS) is a rare bone and soft tissue malignancy driven by chromosomal translocations encoding chimeric transcription factors, such as EWSR1-FLI1,…”
Get full text
Journal Article -
12
Fat induces glucose metabolism in non-transformed liver cells and promotes liver tumorigenesis
Published in Cancer research (Chicago, Ill.) (09-03-2021)“…Hepatic fat accumulation is associated with diabetes and hepatocellular carcinoma (HCC). Here we characterize the metabolic response that high fat availability…”
Get full text
Journal Article -
13
Abstract 692: Pappalysin-1 is a suitable target for T cell receptor transgenic T cells to kill Ewing sarcoma in vivo and in vitro
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Pregnancy-associated plasma protein-A (PAPPA), also known as pappalysin, is a member of the insulin like growth factor (IGF) family. PAPPA acts as a protease,…”
Get full text
Journal Article -
14
Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma
Published in International journal of cancer (15-02-2019)“…Soft‐tissue sarcomas are rare, heterogeneous, and often aggressive mesenchymal cancers. Many of them are associated with poor outcome, partially because…”
Get full text
Journal Article -
15
Human HLA-A02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo
Published in Oncotarget (12-07-2016)“…The endochondral bone protein Chondromodulin-I (CHM1) provides oncogene addiction in Ewing sarcoma (ES). We pre-clinically tested the targetability of CHM1 by…”
Get full text
Journal Article -
16
Abstract A13: Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility
Published in Cancer research (Chicago, Ill.) (01-10-2018)“…Ewing sarcoma (EWS), a pediatric tumor predominantly occurring in children of European ancestry, is characterized by the EWSR1-FLI1 fusion oncogene. We…”
Get full text
Journal Article -
17
Abstract 2970: Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Ewing sarcoma (EWS) is a rare pediatric tumor predominantly occurring in children of European ancestry and is characterized by the pathognomonic EWSR1-FLI1…”
Get full text
Journal Article -
18
Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients
Published in EBioMedicine (01-09-2019)“…Up to 30–40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2–10 years. This is in part…”
Get full text
Journal Article -
19
Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patientsResearch in context
Published in EBioMedicine (01-09-2019)“…Background: Up to 30–40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2–10 years. This…”
Get full text
Journal Article